SCHEMBL2067601

SCHEMBL2067601

CC(=O)Nc1[c]ccnc1Cl

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.36
HTT P42858 3/20 0.34
S100A4 P26447 1/20 0.34
TSHR P16473 1/20 0.33
LMNA P02545 1/20 0.33
ALDH1A1 P00352 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
POLB P06746 3/20 0.33
PIK3C3 Q8NEB9 1/20 0.32
AURKA O14965 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KDM4E B2RXH2 1/20 0.31
PRNP P04156 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067869 0.76 GAA (0.39) L3MBTL1HTTTSHRLMNAALDH1A1
SCHEMBL2067658 0.73 TDP1 (0.41) L3MBTL1TSHRLMNAALDH1A1MEN1
SCHEMBL2068369 0.71 PIK3CD (0.38) HTTLMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL2066950 0.70 LMNA (0.32) LMNA
SCHEMBL11372296 0.69 PTK2 (0.43) PTK2L3MBTL1HTTS100A4TSHR
SCHEMBL5487260 0.69 HSP90AA1 (0.41) LMNAALDH1A1JAK2JAK1TYK2
SCHEMBL5761645 0.67 L3MBTL1 (0.41) PTK2L3MBTL1HTTLMNAJAK2
SCHEMBL6143237 0.66 SMN1; SMN2 (0.63) L3MBTL1HTTLMNAALDH1A1POLB
SCHEMBL28555748 0.66 PTK2 (0.43) PTK2HTTALDH1A1JAK2JAK1
SCHEMBL27877834 0.66 PTK2 (0.47) PTK2HTTS100A4TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 PTK2 413/4885L3MBTL1 2657/4885HTT 1605/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 PTK2 413/4885L3MBTL1 2657/4885HTT 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.